mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy.
cardiac allograft vasculopathy
immunosupression
mTOR Inhibitor
pediatric heart transplantation
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
02
01
2024
received:
12
07
2023
accepted:
12
01
2024
medline:
4
3
2024
pubmed:
4
3
2024
entrez:
4
3
2024
Statut:
ppublish
Résumé
Immunosuppression after heart transplantation (HTX) with mammalian target of rapamycin (mTOR) inhibitors serves as a prophylaxis against rejection and to treat coronary vascular injury. However, there is little data on the early, preventive use of everolimus after pediatric HTX. Retrospective study of 61 pediatric HTX patients (48 cardiomyopathy and 13 congenital heart disease), 28 females, median age 10.1 (range 0.1-17.9) years transplanted between 2008 and 2020. We analyzed survival, rejection, renal function, occurrence of lymphoproliferative disorder, and allograft vasculopathy together with adverse effects of early everolimus therapy combined with low-dose calcineurin inhibitors. Everolimus therapy was started at a median 3.9 (1-14) days after HTX. Median follow-up was 4.3 (range 0.5-11.8) years, cumulative 184 patient years. The estimated 1- and 5-year survival probability was 89% (CI 82%:98%) and 87% (CI 78%:97%). Four patients developed rejection (6.6%) (maximum 2R ISHLT criteria). No patient suffered from chronic renal failure. Three patients (4.9%) developed post-transplant lymphoproliferative disorder. Five patients suffered relevant wound-healing disorders after transplantation, four of them carrying relevant risk factors before HTX (mechanical circulatory support (n = 3), delayed chest closure after HTX (n = 3)). No recipient developed cardiac allograft vasculopathy. Initiating everolimus within the first 14 days after HTX seems to be well tolerated, enabling a low incidence of rejection, post-transplant lymphoproliferative disorders, renal failure, and reveals no evidence of cardiac allograft vasculopathy as well as good overall survival in pediatric heart transplant recipients.
Sections du résumé
BACKGROUND
BACKGROUND
Immunosuppression after heart transplantation (HTX) with mammalian target of rapamycin (mTOR) inhibitors serves as a prophylaxis against rejection and to treat coronary vascular injury. However, there is little data on the early, preventive use of everolimus after pediatric HTX.
METHODS
METHODS
Retrospective study of 61 pediatric HTX patients (48 cardiomyopathy and 13 congenital heart disease), 28 females, median age 10.1 (range 0.1-17.9) years transplanted between 2008 and 2020. We analyzed survival, rejection, renal function, occurrence of lymphoproliferative disorder, and allograft vasculopathy together with adverse effects of early everolimus therapy combined with low-dose calcineurin inhibitors.
RESULTS
RESULTS
Everolimus therapy was started at a median 3.9 (1-14) days after HTX. Median follow-up was 4.3 (range 0.5-11.8) years, cumulative 184 patient years. The estimated 1- and 5-year survival probability was 89% (CI 82%:98%) and 87% (CI 78%:97%). Four patients developed rejection (6.6%) (maximum 2R ISHLT criteria). No patient suffered from chronic renal failure. Three patients (4.9%) developed post-transplant lymphoproliferative disorder. Five patients suffered relevant wound-healing disorders after transplantation, four of them carrying relevant risk factors before HTX (mechanical circulatory support (n = 3), delayed chest closure after HTX (n = 3)). No recipient developed cardiac allograft vasculopathy.
CONCLUSION
CONCLUSIONS
Initiating everolimus within the first 14 days after HTX seems to be well tolerated, enabling a low incidence of rejection, post-transplant lymphoproliferative disorders, renal failure, and reveals no evidence of cardiac allograft vasculopathy as well as good overall survival in pediatric heart transplant recipients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14698Informations de copyright
© 2024 The Authors. Pediatric Transplantation published by Wiley Periodicals LLC.
Références
Rossano JW, Singh TP, Cherikh WS, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: twenty-second pediatric heart transplantation report - 2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019;38(10):1028-1041. doi:10.1016/j.healun.2019.08.002
Webber SA, McCurry K, Zeevi A. Heart and lung transplantation in children. Lancet. 2006;368(9529):53-69. doi:10.1016/S0140-6736(06)68969-1
Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation. 2004;110(25):3858-3865. doi:10.1161/01.CIR.0000150332.42276.69
Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108(1):48-53. doi:10.1161/01.CIR.0000070421.38604.2B
Almond C, Sleeper LA, Rossano JW, et al. The TEAMMATE trial: study design and rationale of the first pediatric heart transplant randomized clinical trial. J Heart Lung Transplant. 2020;39(4):S207-S208. doi:10.1016/j.healun.2020.01.825
Buchwald A, Winkler K, Epting T. Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA. BMC Clin Pharmacol. 2012;12:2.
Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089-2100. doi:10.1111/j.1523-1755.2005.00365.x
Fleck TP, Nieratschker P, Stiller B. Routine surveillance biopsies after pediatric heart transplantation - are they still necessary? J Heart Lung Transplant. 2019;38(4):S473. doi:10.1016/j.healun.2019.01.1204
Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710-1720. doi:10.1016/j.healun.2005.03.019
Spehl MS, Fleck T, Schauer F, Meiss F, Stiller B. Everolimus-associated perianal ulcers in an eight-month-old heart transplant recipient. Pediatr Transplant. 2018;22(1):e13072. doi:10.1111/petr.13072
Ameduri RK, Zheng J, Schechtman KB, et al. Has late rejection decreased in pediatric heart transplantation in the current era? A multi-institutional study. J Heart Lung Transplant. 2012;31(9):980-986. doi:10.1016/j.healun.2012.05.016
Colvin M, Smith JM, Hadley N, et al. OPTN/SRTR 2018 Annual Data Report: Heart. Scientific registry of transplant recipients; 2018.
Chin C, Naftel DC, Singh TP, et al. Risk factors for recurrent rejection in pediatric heart transplantation: a multicenter experience. J Heart Lung Transplant. 2004;23(2):178-185. doi:10.1016/S1053-2498(03)00059-7
Feingold B, Zheng J, Law YM, et al. Risk factors for late renal dysfunction after pediatric heart transplantation: a multi-institutional study. Pediatr Transplant. 2011;15(7):699-705. doi:10.1111/j.1399-3046.2011.01564.x
Rossano JW, Cherikh WS, Chambers DC, et al. The registry of the International Society for Heart and Lung Transplantation: twentieth pediatric heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1060-1069. doi:10.1016/j.healun.2017.07.018
Rossano JW, Cherikh WS, Chambers DC, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: twenty-first pediatric heart transplantation report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1184-1195. doi:10.1016/j.healun.2018.07.018
Salonen R, Jahnukainen T, Nikkilä A. Enden K long-term mortality in pediatric solid organ recipients-a nationwide study. Pediatr Transplant. 2023;27:e14463. doi:10.1111/petr.14463
Gossett JG, Canter C, Zheng J, et al. Decline in rejection in the first year after pediatric cardiac transplantation: a multi-institutional study. J Heart Lung Transplant. 2010;29:625-632. doi:10.1016/j.healun.2009.12.009
Zinn MD, Wallendorf MJ, Simpson KE, Osborne AD, Kirklin JK, Canter CE. Impact of routine surveillance biopsy intensity on the diagnosis of moderate to severe cellular rejection and survival after pediatric heart transplantation. Pediatr Transplant. 2018;22(3):e13131. doi:10.1111/petr.13131
Viganò M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant. 2007;26(6):584-592. doi:10.1016/j.healun.2007.03.005
Khoury M, Conway J, Gossett JG, et al. Cardiac allograft vasculopathy in pediatric heart transplant recipients does early-onset portend a worse prognosis? J Heart Lung Transplant. 2022;41:578-588. doi:10.1016/j.healun.2022.01.012
Pahl E, Naftel DC, Kuhn MA, et al. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study. J Heart Lung Transplant. 2005;24(6):645-651. doi:10.1016/j.healun.2004.03.021
Bogle C, Cantor R, Koehl D, et al. Obesity and dyslipidemia predict cardiac allograft vasculopathy and graft loss in children and adolescents post-heart transplant: a PHTS multi-institutional analysis. Pediatr Transplant. 2022;26(5):e14244. doi:10.1111/petr.14244
Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847-858. doi:10.1056/NEJMoa022171
Rossano JW, Jefferies JL, Pahl E, et al. Use of sirolimus in pediatric heart transplant patients: a multi-institutional study from the pediatric heart transplant study group. J Heart Lung Transplant. 2017;36(4):427-433. doi:10.1016/j.healun.2016.09.009
Manlhiot C, Pollock-BarZiv SM, Holmes C, et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant. 2010;29(6):648-657. doi:10.1016/j.healun.2010.01.013
Katz BZ, Pahl E, Crawford SE, et al. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr Transplant. 2007;11(1):58-65. doi:10.1111/j.1399-3046.2006.00609.x
Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human EBV-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA. 2000;97:4285-4290.
Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984;311(11):699-705. doi:10.1056/NEJM198409133111103
Sachdeva R, Blaszak RT, Ainley KA, Parker JG, Morrow WR, Frazier EA. Determinants of renal function in pediatric heart transplant recipients: long-term follow-up study. J Heart Lung Transplant. 2007;26(2):108-113. doi:10.1016/j.healun.2006.11.008
Gustafsson F, Andreassen AK, Andersson B, et al. Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: long-term follow-up from the randomized SCHEDULE study. Transplantation. 2020;104(1):154-164. doi:10.1097/TP.0000000000002702
Newland DM, Rosete BE, Law YM, et al. Assessment of the adverse effects of sirolimus versus everolimus in pediatric heart transplant recipients. Pediatr Transplant. 2023;27:e14487. doi:10.1111/petr.14487
Asleh R, Alnsasra H, Lerman A, et al. Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients. Am J Transplant. 2020;21:626-635. doi:10.1111/ajt.16155
Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant. 2007;21(4):460-465. doi:10.1111/j.1399-0012.2007.00668.x
Lehmkuhl HB, Arizon J, Viganò M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation. 2009;88(1):115-122. doi:10.1097/TP.0b013e3181aacd22
Potena L, Pellegrini C, Grigioni F, et al. Optimizing the safety profile of everolimus by delayed initiation in de novo heart transplant recipients: results of the prospective randomized study EVERHEART. Transplantation. 2018;102(3):493-501. doi:10.1097/TP.0000000000001945
Singh TP, Naftel DC, Webber S, et al. Hyperlipidemia in children after heart transplantation. J Heart Lung Transplant. 2006;25(10):1199-1205. doi:10.1016/j.healun.2006.06.003
Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. J Heart Lung Transplant. 2004;23(3):317-322. doi:10.1016/S1053-2498(03)00193-1